Current Status of Nitrosoureas Under Development in Japan

  • M. Ogawa
  • S. Fujimoto
Part of the Recent Results in Cancer Research book series (RECENTCANCER, volume 76)


Three nitrosourea compounds [1–4], BCNU, CCNU, and methyl CCNU (MeCCNU) have demonstrated clinical efficacy in a variety of human malignancies including lung cancer, gastrointestinal tumors, lymphomas, melanomas, and brain tumors. But delayed and cumulative hematologic toxicity has been an obstacle to clinical use.


Hematologic Toxicity Small Cell Carcinoma Polycythemia Vera Lewis Lung Carcinoma Complete Tumor Regression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Symposium on the Nitrosoureas. Cancer Chemother Rep (Part 3) 4:1–35Google Scholar
  2. 2.
    Proceedings of the Seventh New Drug Seminar on the Nitrosoureas. Cancer Treat Rep 60:645–807Google Scholar
  3. 3.
    Wasserman TH, Slavik M, Carter SK (1974) Review of CCNU in clinical cancer therapy. Cancer Treat Rev 1:131–151CrossRefGoogle Scholar
  4. 4.
    Wasserman TH, Slavik M, Carter SK (1974) Methyl CCNU in clinical cancer therapy. Cancer Treat Rev 1:251–269PubMedCrossRefGoogle Scholar
  5. 5.
    Schein PS, O’Connel MJ, Blom J, Magrath IT, Bergevin P, Wiernik PH, Ziegler JI, Devita VT (1974) Clinical antitumor activity and toxicity of streptozotocin (NSC-85998). Cancer 34:993–1000PubMedCrossRefGoogle Scholar
  6. 6.
    Schein PS, Panasci L, Wooley PV, Anderson T (1976) Pharmacology of chlorozotocin (NSC-178248), a new nitrosourea antitumor agent. Cancer Treat Rept 60:801–805Google Scholar
  7. 7.
    Fox PA, Panasci LC, Schein PS (1977) Biological and biochemical properties of l-(2-chloroethyl)-3-(/5-D-glucopyranosyl)-l-nitrosourea (NSC D254157), a nitrosourea with reduced bone marrow toxicity. Cancer Res 37:783–787PubMedGoogle Scholar
  8. 8.
    Hoth D, Schein P, Macdonald J, Buscaglia D, Haller D (1977) Phase I trial and clinical pharmacology of chlorozotocin (CLZ). Proc Am Assoc Cancer Res 18:309Google Scholar
  9. 9.
    Gralla RJ, Tan CTC, Young CW (1979) Phase I trial of chlorozotocin. Cancer Treat Rep 63:17–20PubMedGoogle Scholar
  10. 10.
    Muggia FM (to be published) Clinical trials in cancer; general concepts and methodologies. Cancer Clin TrialsGoogle Scholar
  11. 11.
    Kimura K (1965) Chemotherapy of acute leukemia with special reference to criteria for evaluation of therapeutic effect. In: Advances in chemotherapy of acute leukemia under the Japan-US cooperative science program. Sept. 27–28. Bethesda, USA pp 21–23Google Scholar
  12. 12.
    Kimura K, Sakai Y, Konda C, Kashiwada N, Kitahara, T, Inagaki J, Mikuni M, Sakano T (1969) Chemotherapy of malignant lymphomas. Saishin Igaku 24:816–824PubMedGoogle Scholar
  13. 13.
    Arakawa M, Shimizu F, Okada N (1974) Effect of l-(4-amino-2-methylpyrimidin-5-yl)-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride on leukemia L-1210. Gann 65:191Google Scholar
  14. 14.
    Shimizu F, Arakawa M (1975) Effect of 3-[(4-ammo-2-methyl-5-pyrimidinyl)methyl]-l-(2-chloroethyl)-l-nitrosourea hydrochlorize on lymphoid leukemia L-1210. Gann 66:149–154PubMedGoogle Scholar
  15. 15.
    Nakamura T, Sasada M, TashimaM, Yamamoto K, Uchida M, Sawada H, Uchino H (1978) Biological and biochemical mechanism of action of ACNU has been studied in L1210 cells in culture and human leukemic leucocytes obtained from patients with leukemia in vitro. Cancer Chemother 5:991–1000Google Scholar
  16. 16.
    Shigehara E, Tanaka M (1978) Whole body autographic studies on tissue distribution of 3-[(4-amino-2-methyl-5-pyrimidinyl)methyl-l-(2-chloroethyl)-l-nitrosourea hydrochloride in tumor-bearing mice and rats. Gann 69:709–714PubMedGoogle Scholar
  17. 17.
    Shimizu F, Okada N, Arakawa M (1975) Antitumor effect of ACNU (3); Effect on transplantable tumors in mice. Proc Jpn Cancer Assoc 34:302Google Scholar
  18. 18.
    Cooperative Study Group of Phase I Study on ACNU: Phase I study of l-(4-amino-2-methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU). Jpn J Clin Oncol 6:55–62Google Scholar
  19. 19.
    Saito T, Yokoyama M, Himori T, Ujiie S, Sugawara N, Sugiyama Z, Kitada K (1977) Phase I and preliminary phase II study of l-(4-amino-2-methyl-5-pyrimidyl)methyl-3-(2-chloroethyl)-3-nitrosourea hydrochloride (ACNU) administered by intermittent dose schedule. Cancer Chemother 4:991–1004Google Scholar
  20. 20.
    Ogawa M, Inagaki J, Horikoshi N, Inoue K, Chinen T, Ueoka H, Nagtira E, Fujimoto S, Murakami M, Ota K (1978) A clinical study on a new water-soluble nitrosourea derivative (ACNU). Cancer Chemother 5:105–110Google Scholar
  21. 21.
    Kimura I, Harada H, Ohnoshi T, Urabe Y, Fujii M, Machida K, Murakami N (1978) Clinical trial of l-(4-ammo-2-methyl-5-pyrimidinyl)methyl-3-(2-cWoroethyl)-3-rußrosourea hydrochloride (ACNU). Cancer Chemother 5:767–772Google Scholar
  22. 22.
    Ishii Y, Hattori T (Tokyo Cancer Chemotherapy Cooperative Study) (1978) Cooperative study on comparison between ACNU treatment and combined treatment with ACNU and OK-432. Cancer Chemother 5:1195–1203Google Scholar
  23. 23.
    Ishiyama K (1978) Clinical results of ACNU on gastrointestinal tumors. Rinsho Kenkyu 55:309–312Google Scholar
  24. 24.
    Honjo H, Fujii M, Tsuda S, Kimura T, Ohshima K, Yamamoto T, Murakami A (1979) Clinical experience of ACNU against gynecological tumors. Basic Pharmacol Ther 7:163–171Google Scholar
  25. 25.
    Saijo N, Kawase I, Nishiwaki Y, Suzuki A, Niitani H (1977) Phase II study of ACNU [l-(4-arnino-2-methyl-5-pyrimidinyl) methyl-3-(2-chloroethyl)-3-nitrosourea hydrochlo-ride] for primary lung cancer and nodular pulmonary metastases. Cancer Chemother 4:579–584Google Scholar
  26. 26.
    Saijo N, Nishiwaki Y, Kawase I, Kobayashi T, Suzuki A, Niitani H (1978) Effect of ACNU on primary lung cancer, methothelioma, and metastatic pulmonary tumors. Cancer Treat Rep 62:139–141PubMedGoogle Scholar
  27. 27.
    Hori M, Nakagawa H, Hasegawa H, Mogami H, Hayakawa T, Nakata Y (1978) Chemotherapy of malignant glioma with the new nitrosourea derivative (ACNU). Cancer Chemother 5:773–778Google Scholar
  28. 28.
    Saito Y, Nakaya Y, Muraoka K, Fujiwara T (1978) Chemotherapy of brain tumors with nitrosourea derivative (ACNU). Cancer Chemother 5:779–794Google Scholar
  29. 29.
    Majima H, Oguro M, Takagi T (1978) Treatment of malignant lymphoma with ACNU. Cancer Chemother 5:355–359Google Scholar
  30. 30.
    Takubo T, Masaoka T, Nakamura H, Ueda T, Shibata H, Yoshitake J (1978) ACNU treatment of blood malignancy. Cancer Chemother 5:599–603Google Scholar
  31. 31.
    Inoue K, Inagaki J, Horikoshi N, Nagura E, Ueoka H, Murosaki S, Kobayashi T, Sujimoto S, Ogawa M, Saito T (1979) Clinical effect of DTIC containing combination chemotherapy against malignant melanoma and sarcomas. Proc Annu Meet Chemother 149Google Scholar
  32. 32.
    Machinami T, Nishiyama S, Kikuchi K, Suami T (1975) Synthesis of (2-chloroethyl)-nitrosourea derivatives of carbohydrate. Bull Chem Soc Jpn 48:3763–3764CrossRefGoogle Scholar
  33. 33.
    Yoshida K, Hoshi A, Kuretani K (1976) Mechanism of action of l-(2-chloroethyl)-3-(ß-D-glucopyranosyl)-l-nitrosourea (GANU) in vitro. Proc Jpn Cancer Assoc 486Google Scholar
  34. 34.
    Hisamatsu T, Uchida T (1977) Effect of l-(2-chloroethyl)-3-(£-D-glucopyranosyl)-l-nitrosourea on experimental tumors. Gann 68:819–824PubMedGoogle Scholar
  35. 35.
    Aoshima M, Sakurai Y (1977) Comparative studies on the antitumor activity and the bone marrow toxicity of l-(/3-D-glucopyranosyl)-3-(2-chloroethyl)-3-nitrosourea and 2-[3-(2-chloroethyl)-3-nitrosoureido)-D-glycopyranose. Gann 68: 247–250PubMedGoogle Scholar
  36. 36.
    Fox PA, Panasci LC, Schein PS (1977) Biological and biochemical properties of l-(2-chloroethyl)-3-(ß-D-glucopyranosyl)-l-nitrosourea (NSC D254157), a nitrosourea with reduced bone marrow toxicity. Cancer Res 37:783–787PubMedGoogle Scholar
  37. 37.
    Sekido S, Ninomiya K, Iwasaki M (to be publisched) Biological activity of l-(2-chloroethyl)-3-(methyl-a-D-glucopyranos-6-yl)-l-nitrosourea (MCNU; NSC-D270516); A new antitumor agent. Cancer Treat RepGoogle Scholar
  38. 38.
    Fujimoto S, Ogawa M Unpublished workGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1981

Authors and Affiliations

  • M. Ogawa
    • 1
  • S. Fujimoto
    • 1
  1. 1.Division of Clinical Chemotherapy, Cancer Chemotherapy CenterJapanese Foundation for Cancer ResearchToshima-ku, Tokyo 170Japan

Personalised recommendations